Journal
NPJ PARKINSONS DISEASE
Volume 8, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41531-022-00345-4
Keywords
-
Categories
Funding
- National Health and Medical Research Council of Australia [1181864, SC1999]
Ask authors/readers for more resources
This study used the Bradford Hill model of causation to evaluate the impact of iron and copper levels, as well as iron- and copper-associated proteins and genes, on the etiology of Parkinson's disease. The findings suggest that dysregulation of iron and copper is causally linked to the development of Parkinson's disease.
The Bradford Hill model evaluates the causal inference of one variable on another by assessing whether evidence of the suspected causal variable aligns with a set of nine criteria proposed by Bradford Hill, each representing fundamental tenets of a causal relationship. The aim of this study was to use the Bradford Hill model of causation to assess the level of empirical evidence supporting our hypotheses that alterations to iron and copper levels, and iron- and copper-associated proteins and genes, contribute to Parkinson's disease etiology. We conducted a systematic review of all available articles published to September 2019 in four online databases. 8437 articles matching search criteria were screened for pre-defined inclusion and exclusion criteria. 181 studies met study criteria and were subsequently evaluated for study quality using established quality assessment tools. Studies meeting criteria for moderate to high quality of study design (n = 155) were analyzed according to the Bradford Hill model of causation. Evidence from studies considered of high quality (n = 73) supported a causal role for iron dysregulation in Parkinson's disease. A causal role for copper dysregulation in Parkinson's disease was also supported by high quality studies, although substantially fewer studies investigated copper in this disorder (n = 25) compared with iron. The available evidence supports an etiological role for iron and copper dysregulation in Parkinson's disease, substantiating current clinical trials of therapeutic interventions targeting alterations in brain levels of these metals in Parkinson's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available